Abstract
Serious adverse reactions among new smear-positive patients were studied in a programme setting in Kyrgyzstan. Two per cent of patients on tuberculosis (TB) treatment had to interrupt treatment for > or =1 week, and more than 80% of the reactions occurred during the first month of treatment. Pyrazinamide was the most common causative agent, followed by rifampicin.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adult
-
Antitubercular Agents / adverse effects*
-
Antitubercular Agents / therapeutic use
-
Communicable Disease Control / methods
-
Humans
-
Kyrgyzstan / epidemiology
-
Pyrazinamide / adverse effects
-
Pyrazinamide / therapeutic use
-
Rifampin / adverse effects
-
Rifampin / therapeutic use
-
Sputum / microbiology
-
Tuberculosis / drug therapy*
Substances
-
Antitubercular Agents
-
Pyrazinamide
-
Rifampin